Navigation Links
Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer
Date:11/19/2012

BETHESDA, Md., Nov. 19, 2012 /PRNewswire-USNewswire/ -- Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, today announced a major expansion of its research collaboration with Pfizer Inc. designed to discover new drugs to treat people with the most common mutation of CF, Delta F508.

Under the new six-year pre-clinical research program with Pfizer, CFFT will invest up to $58 million to speed the discovery and development of potential therapies that target the underlying cause of cystic fibrosis. The program's goal is to advance one or more drug candidates into the clinic by the end of the multiyear collaboration.

"We are excited to expand our efforts with Pfizer to accelerate the development of more therapies that treat the root cause of CF and benefit the greatest number of people with the disease," said Robert J. Beall, Ph.D., president and CEO of the CF Foundation. "Pfizer brings impressive technical and scientific expertise, along with its commitment to improving the lives of people with cystic fibrosis."

In people with the Delta F508 mutation, a defective protein called CFTR does not fold correctly and is unable to reach the cell surface, where it is needed to help maintain the proper flow of salt and fluids into the airways. As a result, thick secretions form in the airways, leading to serious lung infections and lung damage. Nearly 90 percent of people with CF have at least one copy of the Delta F508 mutation. 

The collaboration will focus on identifying therapies that help restore normal function of the defective protein. Pfizer researchers will draw on their leading expertise in developing therapies that help mutated proteins fold and route correctly within the cell.

"Innovative collaborations between industry and patient organizations are increasingly critical in expe
'/>"/>

SOURCE Cystic Fibrosis Foundation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savara Pharmaceuticals AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
2. FDA Advisory Committee supports use of tobramycin inhalation powder from Novartis for patients with cystic fibrosis
3. OrPro Therapeutics Receives NIH Grant Award to Advance Development of Recombinant Thioredoxin for Treatment of Cystic Fibrosis
4. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
5. Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in the U.S. Senate
6. Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in House of Representatives
7. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
8. Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
9. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
10. Synteract and Rempex Partner in "Great Strides" Walk to Support Cystic Fibrosis Cure
11. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Fla. , Jan. 23, 2015  Today the U.S. ... Novartis, Bexsero® for the prevention of serogroup B ... Bexsero and Pfizer,s vaccine Trumenba®, which received FDA approval ... prevent this devastating disease. "I have ...
(Date:1/23/2015)... analysis of Centers for Medicare and Medicaid Services, (CMS) ... percent of seniors chose lower-cost preferred pharmacy plans that ... The findings were released by Drug Channels . ... of Medicare Part D," said Pharmaceutical Care Management Association ...
(Date:1/23/2015)... 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating ... Inc. ("Advaxis" or the "Company") (NASDAQ: ADXS ... duties to shareholders. On January 21, 2015, ... that Advaxis had misrepresented the clinical data for its ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... Highlights GeneXpert(R) System ... ... (Nasdaq:,CPHD) today announced the U.S. Food & Drug Administration (FDA) ... the Clinical Laboratory Improvement Amendments (CLIA).,The new test is designed ...
... from the Landmark ATHENA ... Study, PARIS, Nov. 4 , ... 14.00-15.00am CET, Background:, -- AF is a growing health concern directly responsible for ... a global prospective database like RecordAF, which takes a closer look ...
Cached Medicine Technology:Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 2Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 3Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA 4Tackling Atrial Fibrillation and Associated Cardiovascular Risk 2
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Joan Lunden, ... keynote speaker at the upcoming 32nd Annual Miami ... Physicians’ Education Resource®, LLC (PER®) , shares that ... have gone undetected if she had not followed up ...
(Date:1/22/2015)... 22, 2015 IsoComforter, Inc. has introduced the ... patented IsoTube design to treat specific body parts and muscle ... progressive and easy to use patented cold therapy machine with ... related orthopedic and muscle injuries. IsoComforter has become the ...
(Date:1/22/2015)... As interest in the value of spiritual support as ... Rev. Eric J. Hall , president and CEO of the ... the keynote speaker on January 27 at an international summit ... The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual Care,” ...
(Date:1/22/2015)... Step into a macabre world where ... of Virginia. Wicked Plants, the Museum’s latest featured exhibition, ... poisonous, carnivorous and diabolical plants inside of a dilapidated, ... the biochemical, physical and neurological processes between botanicals and ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... Dec. 3 The four million Americans who,suffer from ... today with,the announcement of an unprecedented research program to ... treatment of CFS. The,announcement was made by the CFIDS ... Accelerate CFS Research Initiative. , ...
... have identified a molecular cause behind the ravages of ... how a natural process for fighting cancer in younger ... senescence, the process by which biological cells stop dividing ... was shown to trigger the secretion of proteins that ...
... premiums have slowed to less than half the growth rate ... waste in the health care system continue to fuel underlying ... , , Prepared by ... "The Factors Fueling Rising Healthcare Costs 2008" examines the causes ...
... replace mammography for screening yet, experts say, , , WEDNESDAY, ... techniques will help doctors diagnose and stage breast cancer, ... detection of breast cancer. , Both tests -- breast-specific ... rely on the use of radiotracers to detect cancer ...
... have adopted,New Jersey,s unique and successful "Mayors Wellness Campaign" (MWC) ... Times Free Press on Monday,reported that the cities of Athens ... the New Jersey program through their health plan.,(The article can ... The Mayors Wellness Campaign is an ...
... treatment seems to improve cognitive functioning in patients with ... according to the results of a randomized clinical trial ... study led by Sonia Ancoli-Israel, Ph.D., professor of ... and one of the nation,s preeminent experts in the ...
Cached Medicine News:Health News:New Research Will Benefit Four Million Americans Suffering from Chronic Fatigue Syndrome 2Health News:New Research Will Benefit Four Million Americans Suffering from Chronic Fatigue Syndrome 3Health News:New Research Will Benefit Four Million Americans Suffering from Chronic Fatigue Syndrome 4Health News:Cellular senescence a double-edged sword 2Health News:Cellular senescence a double-edged sword 3Health News:Cellular senescence a double-edged sword 4Health News:Cellular senescence a double-edged sword 5Health News:New Report Shows Slower Premium Growth, But Increasing Pressure to Address Waste in Health Care System 2Health News:New Report Shows Slower Premium Growth, But Increasing Pressure to Address Waste in Health Care System 3Health News:Latest Breast Imaging Techniques Offer New Views 2Health News:Latest Breast Imaging Techniques Offer New Views 3Health News:New Jersey's 'Mayors Wellness Campaign' Goes National! 2Health News:Treating sleep apnea in Alzheimer's patients helps cognition 2Health News:Treating sleep apnea in Alzheimer's patients helps cognition 3
The combination of new measuring principle - Pupil Zone Imaging Method - and unique technology - SLD - offers high accuracy and reliability in refraction measurement....
... Module ACM-8 loads and unloads two centrifuges ... Identification via Cap Recognition the tube type ... in batches of three 5 position racks ... the single centrifuge ACM can be offered ...
... The Recapping System RCS 800 closes various ... efficient and easy way. Different tube heights and ... sealed tubes can be used for send-outs. The ... RSD 800, Aliquoting System RSD 800 and High ...
... detect sequences of the following viruses: ... and 3; influenza virus A and ... and B. Laboratories may use ... *Analyte Specific Reagents. Analytical ...
Medicine Products: